[Environment and cardiovascular health: causes, consequences and opportunities in prevention and treatment].
Jordi BañerasJosep Iglesies-GrauMaría Téllez-PlazaVicente ArrarteNéstor Báez-FerrerBegoña BenitoRaquel Campuzano RuizAlberto CecconiAlberto Domínguez-RodríguezAntonio Rodríguez-SinovasFrancisco UjuetaCarlos VozziGervasio A LamasAna Navas-AciénPublished in: Revista espanola de cardiologia (2022)
The environment is a strong determinant of cardiovascular health. Environmental cardiology studies the contribution of environmental exposures with the aim of minimizing the harmful influences of pollution and promoting cardiovascular health through specific preventive or therapeutic strategies. The present review focuses on particulate matter and metals, which are the pollutants with the strongest level of scientific evidence, and includes possible interventions. Legislation, mitigation and control of pollutants in air, water and food, as well as environmental policies for heart-healthy spaces, are key measures for cardiovascular health. Individual strategies include the chelation of divalent metals such as lead and cadmium, metals that can only be removed from the body via chelation. The TACT (Trial to Assess Chelation Therapy, NCT00044213) clinical trial demonstrated cardiovascular benefit in patients with a previous myocardial infarction, especially in those with diabetes. Currently, the TACT2 trial (NCT02733185) is replicating the TACT results in people with diabetes. Data from the United States and Argentina have also shown the potential usefulness of chelation in severe peripheral arterial disease. More research and action in environmental cardiology could substantially help to improve the prevention and treatment of cardiovascular disease.
Keyphrases
- human health
- risk assessment
- particulate matter
- cardiovascular disease
- climate change
- clinical trial
- heavy metals
- air pollution
- type diabetes
- study protocol
- health risk assessment
- phase ii
- heart failure
- health risk
- cardiac surgery
- public health
- life cycle
- randomized controlled trial
- left ventricular
- acute kidney injury
- cardiovascular events
- combination therapy
- metabolic syndrome
- physical activity
- open label
- mesenchymal stem cells
- double blind
- insulin resistance
- thoracic surgery
- bone marrow
- weight loss
- case control